Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 65862-595

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 65862-595). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Divalproex Fig1)

A cumulative distribution plot comparing the percentage reduction in complex partial seizure (CPS) rate between patients taking Divalproex Sodium delayed-release tablets and those taking placebo. The x-axis represents the percentage of patients, and the y-axis shows the percent reduction in CPS rate with improvement or worsening indicated. Two lines are shown: one for Divalproex Sodium delayed-release tablets and one for placebo.*

FDA Label Image

Figure 2 (Divalproex Fig2)

A line graph showing the percentage reduction in CPS rate versus the percentage of patients for high dose and low dose Divalproex Sodium delayed-release tablets. The x-axis represents the percentage of patients from 0 to 100, while the y-axis shows the percentage reduction in CPS rate from -100% (worsening) to 100% (improvement). Two lines compare high and low dose effects.*

FDA Label Image

Figure-3 (Divalproex Fig3)

A bar graph comparing values between placebo and Divalproex Sodium extended-release tablets. The graph shows two vertical bars labeled with values of 0.6 for placebo and 1.2 for Divalproex Sodium extended-release tablets, with a significance marker (p=0.006).*

FDA Label Image

Package Label-principal Display Panel (250 mg (100 Tablets Bottle))

Label for Divalproex Sodium Extended-Release Tablets USP, 250 mg strength with valproic acid activity, film-coated and extended-release, in a 100-tablet package. The label indicates once-daily dosing and includes storage instructions, distributor Aurobindo Pharma USA, Inc., and manufacturing origin in India. The label also has a barcode and usage instructions referencing the medication guide for pharmacists.*

FDA Label Image

Package Label-principal Display Panel (250 mg Blister Carton (10 x 10 Unit-dose))

Packaging label for Divalproex Sodium Extended-Release Tablets USP, 250 mg, 100 tablets (10 x 10 unit-dose) by Aurobindo Pharma Limited. The label indicates once-daily dosing and highlights the strength as 250 mg with Valproic Acid Activity. The label includes NDC 65862-594-10 and states the product is for prescription use only.*

FDA Label Image

Package Label-principal Display Panel (500 mg (100 Tablets Bottle))

Label for Divalproex Sodium Extended-Release Tablets USP 500 mg film-coated tablets. Contains 100 tablets with valproic acid activity. Distributed by Aurobindo Pharma USA, made in India. Directions include storing at controlled room temperature and dispensing medication guide to patients. Contains barcode and coding area for printing.*

FDA Label Image

Package Label-principal Display Panel (500 mg Blister Carton (10 x 10 Unit-dose))

Packaging label for Divalproex Sodium Extended-Release Tablets USP 500 mg with valproic acid activity, film-coated, once-daily dosing. The box contains 100 tablets (10 x 10 unit-dose) and is labeled as Rx only. Manufactured by Aurobindo Pharma Limited, the package includes dosing, storage, and pharmacist dispensing instructions.*

FDA Label Image

Structure (Divalproex Str)

Chemical structure diagram of divalproex sodium, showing the molecular arrangement including sodium ions and organic groups typical of this compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.